- Details
- Ashish Kamat and Kari Tikkinen discuss guidelines on thromboprophylaxis in urological surgery. Dr. Tikkinen gives a step-by-step guide through deciding to use thromboprophylaxis, starting with demonstrating that prophylaxis works and then discussing what constitutes a need for thromboprophylaxis for the patient. They also discuss cases where the guidelines may falter and how to troubleshoot in tho...
|
- Details
- Niyati Lobo joins Ashish Kamat in a conversation about the updated European Association of Urology (EAU) prognostic risk groups and whether or not the updates appropriately consider patients treated with BCG. Dr. Lobo discusses the applicability of the updated groups in a contemporary cohort of non-muscle-invasive bladder cancer (NMIBC) patients at MD Anderson treated with bacillus Calmette-Guérin...
|
- Details
- Arlene Siefker-Radtke discusses the perioperative management of urothelial cancer, focusing on the balance between efficacy and toxicity in treatments. She reflects on the standard use of cisplatin-based chemotherapy, its associated long-term side effects, and how nearly half of urothelial cancer patients find this treatment intolerable. Dr. Siefker-Radtke touches on the ongoing debate between Dos...
|
- Details
- Tamer Aboushwareb, Vice President of Medical Affairs, Pacific Edge, Ltd provides an overview of the Cxbladder Monitor urine-based cancer surveillance test and is joined by Neal Shore and Josh Meeks for a discussion on the clinical implications of the use of this test. Several supportive publications are highlighted and Drs Shore, Meeks, and Aboushwareb discuss the Cxbladder Monitor algorithm, its...
|
- Details
- Hikmat Al-Ahmadie and Olivier Elemento join Ashish Kamat to discuss the data on artificial intelligence in cancer, with specific reference to bladder cancer. The discussion includes an overview of the benefits of using AI and deep machine learning to predict tumor types, responses, and diagnoses. The conversation addresses how automation and digitization intersect well with pathology. However, cur...
|
- Details
- Nicholas James joins Alicia Morgans in a discussion of the first results of the novel BladderPath trial examining the role of magnetic resonance imaging (MRI) for bladder cancer staging. BladderPath is a randomized comparison of the time from the initial diagnosis to “correct” treatment among patients with possible muscle-invasive bladder cancer who receive staging with MRI, compared to TURBT. Nic...
|
- Details
- Tamer Aboushwareb, Vice President of Medical Affairs, Pacific Edge, Ltd provides an overview of the Cxbladder Detect urine-based cancer diagnostic test and is joined by Neal Shore and Josh Meeks for a discussion on the clinical implications of the use of this test which is designed for high-risk patients who present with hematuria. Cxbladder is a suite of non-invasive, urine-based laboratory tests...
|
- Details
- Ashish Kamat converses with Patrick Hensley of the University of Kentucky about his 2022 John Quale Travel Award. Dr. Hensley dives deep into his research, which aims to refine patient selection for neoadjuvant chemotherapy for muscle-invasive bladder cancer. His study investigates the predictive capacity of an immunohistochemical (IHC) signature in pre-treatment TURBT specimens. His team's primar...
|
- Details
- Alicia Morgans and Patrick Hensley dive into the complexities surrounding the timing of cystectomy in BCG-unresponsive bladder cancer patients. Dr. Hensley emphasizes the need for a risk-stratified approach, particularly in identifying patients on the BCG failure spectrum, as these patients often present with worse outcomes. Dr. Hensley explains that high-risk patients should receive standard-of-c...
|
- Details
- Petros Grivas speaks with Vadim Koshkin about his groundbreaking research in urothelial cancer imaging. The focus is on Dr. Koshkin's abstract detailing the potential of Fibroblast-Associated Protein (FAP) imaging, a novel technique that targets cells present within the cancer, rather than the cancer cells themselves. The ongoing trial aims to enroll 80 patients with solid malignancies but shows p...
|
